pioglitazone has been researched along with Encapsulating Peritoneal Sclerosis in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Matrix metalloproteinases (MMPs) and transforming growth factor beta (TGF-β) were increased in peritoneal dialysis patients with encapsulating peritoneal sclerosis (EPS) and in chlorhexidine gluconate (CG)-induced peritoneal sclerosing animal models." | 7.78 | Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis. ( Camsari, T; Cavdar, Z; Kolatan, E; Oktay, G; Saglam, F; Sarioglu, S; Yilmaz, O, 2012) |
| "Matrix metalloproteinases (MMPs) and transforming growth factor beta (TGF-β) were increased in peritoneal dialysis patients with encapsulating peritoneal sclerosis (EPS) and in chlorhexidine gluconate (CG)-induced peritoneal sclerosing animal models." | 3.78 | Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis. ( Camsari, T; Cavdar, Z; Kolatan, E; Oktay, G; Saglam, F; Sarioglu, S; Yilmaz, O, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saglam, F | 1 |
| Cavdar, Z | 1 |
| Sarioglu, S | 1 |
| Kolatan, E | 1 |
| Oktay, G | 1 |
| Yilmaz, O | 1 |
| Camsari, T | 1 |
1 other study available for pioglitazone and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis.
Topics: Animals; Female; Matrix Metalloproteinase Inhibitors; Peritoneal Fibrosis; Pioglitazone; Rats; Rats, | 2012 |